Work

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.4373.4373

Authors: Michael Savona, Martin Gutierrez, Mark Lanasa, Changchun Deng, John Kuhn, Lauren Sade, Hari Miskin, Peter Sportelli, Swaroop Vakkalanka, Manish Patel

Institutions: Tennessee Oncology, Duke Medical Center, Columbia University Irving Medical Center, The University of Texas at San Antonio Health Science Center, Sarah Cannon, TG Therapeutics, Inc. (United States), Rhizen Pharmaceuticals (Switzerland)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4232829459

FWCI: 0.892

Cites:

Cited by: 4

Related to: 10